Announcement • Jun 17

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment And Subsequent Therapy With Checkpoint Inhibition In Metastatic MKRAS Pancreatic Cancer

Elicio Therapeutics, Inc. reported preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition. Three patients who received ELI-002 7P during Elicio’s recently completed Phase 2 AMPLIFY-7P study experienced disease progression after treatment and subsequently achieved confirmed complete radiographic and complete metabolic responses after receiving nivolumab-based therapy with concurrent normalization of tumor biomarker CA19-9 levels. Two of the three patients maintained complete responses for at least eight months, with one ongoing complete response at >13 months. In addition, all three patients demonstrated persistent mKRAS-specific T cell responses. These observations provide preliminary clinical support for the hypothesis that ELI-002 7P-induced immune responses may enhance sensitivity to checkpoint inhibition and support prospective evaluation of ELI-002 7P and anti–PD-1 combination strategies. These observations represent the first three patients identified following recurrence after treatment with ELI-002 7P during the Phase 2 AMPLIFY-7P study and subsequent gemcitabine/nab-paclitaxel chemotherapy and nivolumab. Elicio intends to continue monitoring additional patients who participated in the AMPLIFY-7P study and are currently following a similar course of treatment. All three patients were microsatellite stable (MSS) /mismatch repair proficient (MMR-p), a population that has historically demonstrated limited responsiveness to immune checkpoint inhibitors. Published studies evaluating chemotherapy-, checkpoint inhibitor-, or RAS inhibitor-based regimens in metastatic pancreatic cancer have reported complete response rates of approximately 0% to 8%, with durable complete responses rarely observed. Elicio intends to initiate a Phase 1 study in metastatic pancreatic ductal adenocarcinoma designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding. Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial. Elicio is hosting a virtual key opinion leader event on Wednesday, June 24, 2026, at 1:00 PM ET, to further discuss these observations. Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s proprietary AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. ELI-002 7P (7-peptide formulation) was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The Phase 2 AMPLIFY-7P trial included patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. Based on topline results and post-hoc analyses, Elicio has refined its Phase 3 development strategy to focus on patients with lower residual disease burden and extended treatment duration. Elicio intends to initiate a Phase 1 study in metastatic PDAC designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding. Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial. At the time of the Phase 2 AMPLIFY-7P analysis, data for overall survival remained immature. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002. Elicio’s proprietary AMP platform delivers investigational immunotherapy directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In pre-clinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapy directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer in Phase 1 studies. In the future, Elicio plans to expand ELI-002 7P to other indications, including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively.

Announcement • Jun 02

Elicio Therapeutics, Inc. Publishes Preclinical Data On AMP-DNA Adjuvant Technology In Science Advances

Elicio Therapeutics, Inc. announced the publication of a peer-reviewed manuscript in Science Advances, published by the American Association for the Advancement of Science, describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amphiphile (AMP) platform technology. The manuscript, titled “Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs,” highlights the ability of these preclinical novel AMP-DNA adjuvants to drive robust, durable immune responses through targeted delivery to lymph nodes and activation of innate immune pathways. This work further builds on the development of the TLR-9-specific AMP-CpG (ELI-004), providing an expanded portfolio of potent lymph node-targeted AMP immunomodulators. The findings further expand the scientific foundation of Elicio’s AMP platform, which is designed to enhance immune responses by directing therapeutics to the lymph nodes—where immune responses are initiated and coordinated—while minimizing systemic toxicity. Preclinically, AMP-DNA outperformed current clinical and commercial benchmark adjuvants in head-to-head comparisons, inducing substantially more robust cellular immunity. AMP-DNA elicited high frequencies of antigen-specific, polyfunctional CD8+ and CD4+ T cell responses across tissues. Durable immune memory was observed for at least nine months, with rapid and robust recall responses upon antigen re-exposure. Findings were replicated in non-human primates, demonstrating strong cellular and humoral immune responses in a translationally relevant model. AMP-DNA targets lymph nodes to create a localized, highly immunostimulatory environment. Immune activation is driven through TBK1/IFN-I signaling pathways, supporting a differentiated mechanism compared to AMP-CpG which activates TLR-9. Preclinical results demonstrated that AMP-DNA adjuvants significantly enhanced both cellular and humoral immune responses compared to unmodified DNA and clinically relevant adjuvant benchmarks. The technology enabled efficient lymph node delivery and induction of a pro-inflammatory cytokine environment critical for adaptive immunity. In non-human primates, AMP-DNA induced strong T cell responses and high titers of neutralizing antibodies, supporting its potential translational relevance for human applications. Elicio’s lead product candidate, ELI-002, is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. ELI-002 2P (2-peptide formulation) has been studied in the Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017). ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002. ELI-004 is a structurally novel, investigational AMP-modified immune-stimulatory CpG oligonucleotide. CpG oligonucleotide sequences are potent stimulators of TLR-9 which induce activation of innate immune cells, and production of supportive inflammatory effector molecules critical for enhancing innate and adaptive immunity. AMP-modification of CpG oligonucleotides promotes several mechanisms which may enhance tumor-directed immune responses: as an adjuvant administered with an antigen to the peripheral tissue, association with tissue albumin promotes delivery from the injection site to the lymph nodes where targeted uptake can enhance action on key immune cells which promote anti-tumor activity; following local injection into a solid tumor, AMP-mediated retention of CpG sequences concentrates immune activation within the target tumor, likely restricting systemic dissemination to irrelevant or toxicity-inducing sites throughout the body. Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue.

Biotechs earnings growth	25.1%
Revenue growth rate	64.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Jul 2026

Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	N/A	-72	-79	-92	2
12/31/2027	N/A	-57	-62	-69	3
12/31/2026	N/A	-44	-43	-48	4
3/31/2026	N/A	-40	-38	-38	N/A
12/31/2025	N/A	-40	-37	-37	N/A
9/30/2025	N/A	-46	-39	-39	N/A
6/30/2025	N/A	-55	-35	-35	N/A
3/31/2025	N/A	-51	-35	-35	N/A
12/31/2024	N/A	-52	-37	-37	N/A
9/30/2024	N/A	-47	-38	-38	N/A
6/30/2024	N/A	-39	-36	-36	N/A
3/31/2024	N/A	-39	-37	-37	N/A
12/31/2023	N/A	-35	-33	-33	N/A
9/30/2023	N/A	-33	-30	-30	N/A
6/30/2023	N/A	-29	-30	-30	N/A
3/31/2023	N/A	-29	-25	-25	N/A
12/31/2022	N/A	-28	-23	-22	N/A
9/30/2022	N/A	-28	-22	-21	N/A
3/31/2022	N/A	-27	-24	-23	N/A
12/31/2021	N/A	-26	-24	-24	N/A
3/31/2021	N/A	-19	-20	-20	N/A
12/31/2020	N/A	-16	-17	-17	N/A

Data	Last Updated (UTC time)
Company Analysis	2026/07/07 00:55
End of Day Share Price	2026/07/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Mayank Mamtani	B. Riley Securities, Inc.
Soumit Roy	JonesTrading Institutional Services, LLC
Boris Peaker	JonesTrading Institutional Services, LLC

Elicio Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 9.1% to US$10.00

Recent updates

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.024474 million.

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.024474 million.

Insufficient new directors

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Value Benchmark

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment And Subsequent Therapy With Checkpoint Inhibition In Metastatic MKRAS Pancreatic Cancer

Elicio Therapeutics Shares Drop After Phase 2 Pancreatic Cancer Trial Misses Main Goal

New major risk - Share price stability

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics, Inc. Publishes Preclinical Data On AMP-DNA Adjuvant Technology In Science Advances

Aggressively accumulate equity shares and August 15 call options

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

New minor risk - Share price stability

10 mg adjuvant = 100% mKRAS specific T-cell response rate

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

80-90% prob of success

Elicio Therapeutics, Inc. Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIF-7P Trial

Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Elicio Therapeutics, Inc. Announces Additional Immunogenicity Data from the Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P

Elicio Therapeutics, Inc. to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Elicio Therapeutics, Inc. Reports Robust T Cell Responses Across Diverse HLA Background in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics, Inc. Announces Investigator-Initiated Phase 1 Trial to Be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Elicio Therapeutics, Inc. Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-Up Data in Nature Medicine for Minimal Residual Disease Positive, Adjuvant-Stage Patients

New major risk - Revenue and earnings growth

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Growth Index

Elicio Therapeutics, Inc. announced that it expects to receive $10 million in funding

New major risk - Financial position

Elicio Therapeutics, Inc., Annual General Meeting, May 19, 2025

Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer

Director exercised options to buy US$28m worth of stock.

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000003 million.

New minor risk - Share price stability

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

New major risk - Financial position

Elicio Therapeutics, Inc. Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Elicio Therapeutics, Inc. Appoints Robert Connelly as Principal Accounting Officer and Principal Financial Officer

Price target decreased by 9.1% to US$10.00

Less than half of directors are independent

Elicio Therapeutics, Inc., Annual General Meeting, Nov 07, 2024

Elicio Therapeutics, Inc. announced that it expects to receive $20 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering.

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting

New major risk - Financial position

Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding from Gkcc, Llc

Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer

Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 At AACR Special Conference: Pancreatic Cancer

Less than half of directors are independent

Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources